Who are Ticagrelor or Prasugrel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): bivalirudin + clopidogrel + aspirin, Clopidogrel, cilostazol, aspirin + clopidogrel + celecoxib, Clopirin 2, Prasugrel based standard DAPT, Vorapaxar and Clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-or-prasugrel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ticagrelor or Prasugrel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ticagrelor or Prasugrel (Ticagrelor or Prasugrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist. Area: Cardiovascular.

marketed P2Y12 receptor antagonist P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor or Prasugrel (Ticagrelor or Prasugrel) — St. Antonius Hospital. Both ticagrelor and prasugrel are P2Y12 receptor antagonists that inhibit platelet aggregation by blocking ADP-mediated platelet activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ticagrelor or Prasugrel TARGET	Ticagrelor or Prasugrel	St. Antonius Hospital	marketed	P2Y12 receptor antagonist	P2Y12 receptor
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2
Clopirin 2	Clopirin 2	Jeil Pharmaceutical Co., Ltd.	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Prasugrel based standard DAPT	Prasugrel based standard DAPT	Research Maatschap Cardiologen Rotterdam Zuid	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
Vorapaxar and Clopidogrel	Vorapaxar and Clopidogrel	Inova Health Care Services	marketed	Dual antiplatelet agent	PAR-1 (vorapaxar) and P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist class)

First Affiliated Hospital of Harbin Medical University · 4 drugs in this class
Fu Wai Hospital, Beijing, China · 1 drug in this class
Ping-Yen Liu · 1 drug in this class
Samsung Medical Center · 1 drug in this class
St. Antonius Hospital · 1 drug in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor or Prasugrel — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-or-prasugrel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing